HCG is an approved biologic. Its label answers the weight-loss question in capital letters.

Why this note exists

Most of 2026's peptide regulation argument has been about substances with no approval at all — which of them a compounding pharmacy may legally make, decided by advisory-committee vote.[23] HCG sits in a different category and gets discussed as though it sits in the same one. It has been an approved product in the United States since the 1970s, it has a label that states its own negative result, and since March 2020 it has been a licensed biologic, which places it outside the compounding lists entirely.[3][4]

In the index generated on August 15, 2026, 21 of 112 vendors carried an HCG listing — 21 listings, forty-eighth of 83 compounds by vendor coverage.[24] Eleven of those 21 listings state a strength: nine say 5,000 IU and two say 10,000 IU; the other ten name no quantity at all.[24] HCG is also the only one of the 83 compounds where no listing states a milligram size, because the hormone is measured in international units of biological activity rather than mass — so pepmg cannot compute a price per milligram for any of them, and none of them can be ranked on the only measure this site ranks on.[24]

A note on what kind of evidence this is: every efficacy figure below is human data, carrying its design and participant count. One paragraph reports what the label says about animal studies, and is labeled as such. Case reports are called case reports in the same sentence as their finding. Doses appear only as the label published them, and pepmg does not convert a labeled unit into a protocol for a research vial.

The label

Two sentences in capital letters, and three indications

The negative statement appears twice. In CLINICAL PHARMACOLOGY, after describing HCG's action at the luteinizing-hormone receptor, the label states: "HCG HAS NO KNOWN EFFECT ON FAT MOBILIZATION, APPETITE OR SENSE OF HUNGER, OR BODY FAT DISTRIBUTION."[1] Then, opening the indications section: "HCG HAS NOT BEEN DEMONSTRATED TO BE EFFECTIVE ADJUNCTIVE THERAPY IN THE TREATMENT OF OBESITY. THERE IS NO SUBSTANTIAL EVIDENCE THAT IT INCREASES WEIGHT LOSS BEYOND THAT RESULTING FROM CALORIC RESTRICTION, THAT IT CAUSES A MORE ATTRACTIVE OR “NORMAL” DISTRIBUTION OF FAT, OR THAT IT DECREASES THE HUNGER AND DISCOMFORT ASSOCIATED WITH CALORIE-RESTRICTED DIETS."[1] The same two passages, in the same capitals, are in the Novarel label.[2]

Only then does the label list what the drug is for: prepubertal cryptorchidism not due to anatomical obstruction, where the label notes that in most cases descent after HCG "is temporary"; selected cases of hypogonadotropic hypogonadism in males; and induction of ovulation and pregnancy in an anovulatory infertile woman "who has been appropriately pretreated with human menotropins."[1]

The product itself is worth describing, because it is not what a vial marked "HCG" on a research site is. The label describes chorionic gonadotropin "obtained from the human pregnancy urine," "standardized by a biological assay procedure," supplied as a sterile lyophilized powder of 10,000 USP units in a multiple-dose vial with bacteriostatic water as the accompanying diluent.[1] Dosage and administration is headed "Intramuscular Use Only," and the label instructs in capitals: "USE COMPLETELY WITHIN 60 DAYS AFTER RECONSTITUTION. REFRIGERATE AFTER RECONSTITUTION."[1]

Published doses, reported as the label states them and attached to their indication: for prepubertal cryptorchidism, regimens such as 4,000 USP units three times weekly for three weeks, or 500 USP units three times weekly for four to six weeks; for hypogonadotropic hypogonadism in males, 500 to 1,000 USP units three times a week for three weeks then the same dose twice a week for three weeks, or 4,000 USP units three times weekly for six to nine months; for ovulation induction, 5,000 to 10,000 USP units one day after the last dose of menotropins.[1] These are FDA-label doses for the labeled indications by the labeled route. They are not a protocol for anything else, and pepmg does not convert them into one.

The regulatory status

Since March 23, 2020, HCG has not been a "drug" in the sense the compounding fight is about

This is the part that almost never survives into a product page or a forum answer. Under the Biologics Price Competition and Innovation Act, an approved application for a biological product under the Food, Drug, and Cosmetic Act was, ten years after enactment, "deemed to be a license" under section 351 of the Public Health Service Act.[3] FDA's published list of the applications that transitioned on March 23, 2020 contains five chorionic gonadotropin products — under the former NDA numbers 017692, 017055, 017067, 017054 and 017016, first approved between 1973 and 1976 — plus the recombinant choriogonadotropin alfa product Ovidrel.[3] FDA states that these former NDAs "have been removed from FDA's Orange Book and were added to FDA's 'Purple Book'" on that date.[3][5] The current marketed label carries a US License Number rather than an NDA number, which is what that transition looks like on the carton.[1]

FDA spelled out the consequence for compounders in its own notice. The transition "affects compounding under sections 503A and 503B of the FD&C Act because, beginning on March 23, these transitioning biological products will not be eligible for the exemptions for compounded drugs under sections 503A and 503B."[4] The notice then names the substances it expected this to bite: "Outsourcing facilities have recently reported using four bulk drug substances that are affected by the transition: human chorionic gonadotropin, hyaluronidase, follicle stimulating hormone (FSH or urofollitropin) and menotropins."[4] And on the lists themselves: "biological products subject to approval under section 351 of the PHS Act are not eligible for the 503B bulks list because such products are not eligible for the exemptions in section 503B of the FD&C Act."[4]

So the question the July 2026 advisory committee was asked about BPC-157, KPV, TB-500 and the rest — may a pharmacy compound this from bulk powder — is a question that cannot be asked about HCG.[23][4] The lawful supply of HCG in the United States is the licensed product, dispensed on a prescription. pepmg is not characterizing what any vendor sells or how it is made; the point is narrower, and it is about the regulatory category, which is a matter of public record.

The human evidence

One 1973 trial said yes. Everything built to check it said no.

The weight-loss use traces to a protocol published by A.T.W. Simeons in the 1950s: daily low-dose injections alongside a diet of roughly 500 calories.[10][6] The trial the market implicitly cites is Asher and Harper, in the American Journal of Clinical Nutrition in 1973.[7] The investigators who set out to reproduce it describe what it found: "the Asher-Harper study (1973) … had found that the combination of 500 cal diet and HCG had a statistically significant benefit over the diet and placebo combination as evidenced by greater weight loss and decrease in hunger."[8]

They could not reproduce it. In their 1976 study, 51 women aged 18 to 60 were entered into a 32-day prospective, randomized, double-blind comparison of HCG against placebo, on the same diet used in the 1973 trial, weighed six days a week, with injections given by the investigators.[8] Twenty of 25 in the HCG group and 21 of 26 on placebo completed 28 injections, and there was "no statistically significant difference in the means of the two groups in number of injections received, weight loss, percent of weight loss, hip and waist circumference, weight loss per injections, or in hunger ratings."[8]

Designs, participant counts and conclusions as reported in the papers themselves.[8][11][12]

The same year as the 1976 trial and the one after it, two more groups looked. Eleven hospitalized women on 500-calorie diets — six given 125 IU of HCG intramuscularly daily for 30 days, five given diluent only — showed "mean weight loss in the HCG-treated group … nearly identical to that achieved by women given the placebo," with no difference in triceps skinfold thickness or in chest, waist, hip and thigh measurements.[9] A double-blind randomized trial reported in the Western Journal of Medicine in 1977 tested the Simeons claims directly and concluded that "weight loss was identical between the two groups, and there was no evidence for differential effects on hunger, mood or localized body measurements."[10]

Another double-blind negative trial came in 1990: 40 women with a body mass index above 30, all on the same 5,000 kJ per day diet, randomized under double-blind conditions to daily intramuscular HCG or saline six days a week for six weeks, with psychological profile, hunger level, body circumferences, fasting bloods and food records collected at both ends.[11] The authors report that subjects receiving HCG "showed no advantages over those on placebo in respect of any of the variables recorded," and conclude "there is no rationale for the use of HCG injections in the treatment of obesity."[11]

Pooling it, a 1995 criteria-based meta-analysis in the British Journal of Clinical Pharmacology traced published papers relating to eight controlled and 16 uncontrolled trials and scored each for methodological quality on a 100-point scheme.[12] Scores ranged from 16 to 73, "suggesting that most studies were of poor methodological quality"; the authors report that "of the 12 studies scoring 50 or more points, one reported that HCG was a useful adjunct," and conclude: "there is no scientific evidence that HCG is effective in the treatment of obesity; it does not bring about weight-loss of fat-redistribution, nor does it reduce hunger or induce a feeling of well-being."[12]

FDA's consumer-facing summary of the same literature is one sentence from the director of its Office of Unapproved Drugs and Labeling Compliance: "These products are marketed with incredible claims, and people think that if they're losing weight, HCG must be working. But the data simply do not support this; any loss is from severe calorie restriction. Not from the HCG."[6] The same page notes that HCG weight-loss products are typically sold as oral drops, pellets and sprays, and that the 500-calorie diets they are sold with carry their own risks — gallstone formation, electrolyte imbalance and irregular heartbeat.[6]

Nobody is running the trial either

This is not an evidence base that is about to move. A PubMed search on September 2, 2026, restricted to randomized controlled trials of chorionic gonadotropin in obesity or weight reduction, returned six records — of which two are trials of HCG for weight loss, published in 1976 and 1990, and the remaining four are unrelated studies that mention the hormone.[25][8][11] A ClinicalTrials.gov search the same day for studies with chorionic gonadotropin as an intervention and obesity as a condition returned six registered records; all six are reproductive-medicine studies — luteal support, embryo transfer, ovarian response, androgen production — and none tests HCG as a treatment for obesity.[14]

What has continued is commentary. A 2012 piece in the International Journal of Obesity is titled, without hedging, "An unfortunate resurgence of human chorionic gonadotropin use for weight loss."[13] Fourteen years later the listings are still there.[24]

The other half of the market

Where the human evidence in men actually is, and what it is made of

Weight loss is not the only reason HCG is bought. It is also used by men who have suppressed their own testosterone production, and the honest description of that literature is: real, active, and mostly uncontrolled.

The label's male indication is narrow — "selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males" — and there is no approved indication for restoring fertility or testosterone after anabolic or testosterone use.[1] The published human data on that off-label use is led by a 2025 report in Fertility and Sterility: a single-center retrospective cohort of 77 men with previous testosterone use seeking fertility treatment between January 2020 and March 2024, given 3,000 IU of HCG and 75 IU of FSH three times a week.[15] Seventy-four percent showed improvement in sperm concentration, and recovery did not differ between the 50 men who stopped testosterone and the 27 who stayed on it.[15] It is a chart review with no control group and no randomization, its dose is a two-drug regimen, and it says nothing about HCG used alone.[15]

Around it sits a thin, specialized literature: a 2026 review in Andrology of HCG-based clinical treatments for infertile men with non-obstructive azoospermia,[16] and a 2024 case series of six men with congenital hypogonadotropic hypogonadism treated with HCG and recombinant FSH during puberty, in which all six later fathered children — six subjects, reported by the authors as "early evidence of proof of concept."[17] These are studies in diagnosed endocrine disease, run with prescription product under specialist supervision. None of them is a study of HCG bought as a research chemical, and none of them is about body composition.

One more piece of status worth knowing if you compete in anything: the 2026 World Anti-Doping Code prohibited list, section S.2.2.1, prohibits "testosterone-stimulating peptides in males," and the first substance named is chorionic gonadotrophin.[21][22] The entry is written for males; the same section does not name it for females.[22]

Safety

What the label records, and what the case literature does and does not establish

The label's adverse reactions are short: "Headache, irritability, restlessness, depression, fatigue, edema, precocious puberty, gynecomastia and pain at the site of injection."[1] Its warnings concern the fertility setting, where the principal serious reactions are listed as ovarian hyperstimulation, rupture of ovarian cysts with hemoperitoneum, multiple births and arterial thromboembolism, and it records that "anaphylaxis and other hypersensitivity reactions have been reported with urinary-derived HCG products."[1] Contraindications are precocious puberty, prostatic carcinoma or other androgen-dependent neoplasm, and prior allergic reaction.[1] The label also cautions that androgen-driven fluid retention means HCG "should be used with caution in patients with cardiac or renal disease, epilepsy, migraine or asthma."[1]

Animal and non-human data, labeled as such: the label states that "long-term studies in animals have not been performed to evaluate the carcinogenic or mutagenic potential of chorionic gonadotropin," and its teratogenicity paragraph reports defects of forelimbs and central nervous system and altered sex ratio in mice given combined gonadotropin therapy at superovulation doses.[1] Neither of those is human evidence, and the first is a statement that the study does not exist.

Beyond the label, the published harm literature for weight-loss use is case reports, one patient at a time. A 2013 report describes deep vein thrombosis and bilateral pulmonary emboli in a 64-year-old woman who had started the HCG diet two weeks earlier on sublingual drops, with an otherwise unremarkable thrombosis workup, which the authors scored on the Naranjo scale as a probable drug cause.[18] A 2015 report describes ischemic stroke in a 29-year-old woman using recombinant HCG.[19] A 2017 report describes Mycobacterium fortuitum skin infection after self-administered subcutaneous HCG injection at a weight-loss clinic.[20] Case reports establish that something happened in one person. They do not establish incidence, and they do not establish cause. The 2013 authors say the quiet part plainly: "the HCG diet has very few efficacy studies and no significant safety studies associated with its use."[18]

The market

A hormone measured in units, on a site that ranks by price per milligram

HCG is where pepmg's own method runs out, and it is worth saying so. The index sorts on price per milligram, and HCG has no milligram. Of the 21 listings in the August 15, 2026 index, not one states a mass — eleven state international units, nine of them 5,000 IU and two 10,000 IU, and ten state no quantity at all.[24] International units of chorionic gonadotropin are units of biological activity assigned by bioassay, which is exactly how the approved label describes its own standardization.[1] Two vials both marked 5,000 IU are claims about potency, not about how much powder is in them, and pepmg has no way to convert one into the other. HCG is the only one of the 83 compounds in the index where every listing is excluded from price ranking for that reason.[24]

The distance between the two products is the same distance this note started with. The approved article is a urine-derived, bioassay-standardized lyophilized powder, licensed as a biologic, supplied with its own bacteriostatic diluent, labeled intramuscular use only, and discarded 60 days after reconstitution.[1] pepmg makes no claim about the contents of any vendor's vial, and the site carries no vendor links while its link policy is under review.

Three things this note is not saying

First, it is not saying HCG does nothing. It is an established clinical agent with a real mechanism at the luteinizing-hormone receptor, three approved indications, and decades of use in reproductive medicine.[1][17] The negative finding is specific: it concerns weight loss, fat distribution and hunger.[12]

Second, it is not saying the weight-loss question was decided by regulators over the evidence. It was decided by randomized human trials — small ones, run in the 1970s and repeated in 1990, all comparing HCG against placebo on top of the same restricted diet — and the label reflects them.[8][11][12] An older trial is not automatically a weaker one; a 51-person randomized double-blind comparison in 1976 is a randomized double-blind comparison.[8]

Third, it is not saying the case reports prove harm. They describe three individual patients, across fifteen years, in a use with no controlled safety data at all — which is a statement about how little is known, not a rate.[18][19][20]

What it is saying is narrower: HCG is approved, its label prints the weight-loss answer in capital letters before it lists a single indication, the randomized human trials behind that sentence found no advantage over the diet, and since March 23, 2020 the compound has been a licensed biologic that the 503A and 503B compounding exemptions do not reach.[1][3][4]

Questions people are asking